Reverse thermal gels and their use in cell therapy
View Patent ↗Methods are disclosed herein for increasing survival of transplanted cells, either in vitro or in vivo. In additional embodiments, methods are disclosed for treating a subject with a spinal cord injury or a neurodegenerative disorder. The methods include administering to a subject a therapeutically effective amount of cells, such as bone marrow stromal cells, and a therapeutically effective amount of a reverse thermal gel composition. The reverse thermal gel compositing includes a triblock copolymer, or pharmaceutically acceptable salt thereof, having the structure B-A-B in which A is one of a polyurethane or poly(ester urethane) group that comprises one or more pendant active groups, blocked active groups or active agents and B is a hydrophilic block, wherein the composition is a gel at 25° C.-40° C. and a liquid solution at a lower temperature.
1. A method for increasing cell survival in a subject, comprising administering to a subject a therapeutically effective amount of a cell; and administering to the subject a therapeutically effective amount of a reverse thermal gel composition comprising a triblock copolymer, or a pharmaceutically acceptable salt thereof, having the structure B-A-B in which A is one of a polyurethane or a poly(ester urethane) group that comprises one or more pendant amine groups, blocked amine groups or active agents and B is a hydrophilic block, wherein the composition gels between 25° C. to 40° C. and is a liquid solution at a lower temperature, and wherein A is a copolymer of a diol and a diisocyanate, thereby increasing the survival of the cell in the subject.
2. The method of claim 1 , wherein the cell is a mesenchymal stem cell or a bone marrow stromal cell.
3. The method of claim 1 , wherein the subject has a neurodegenerative disorder, a stroke or a spinal cord injury.
4. The method of claim 3 , comprising administering a therapeutically effective amount of the mesenchymal cell and the reverse thermal gel composition to the central nervous system or the peripheral nervous system.
5. The method of claim 4 , comprising administering the cell and the reverse thermal gel composition in an intraneural transplant.
6. The method of claim 1 , wherein the diol is an amino-substituted or N-substituted serinol in which the N is substituted with one of a hydrogen, a protective group, or an active agent.
7. The method of claim 6 , wherein the N of the N-substituted serinol is —NHR in which R is a protective group.
8. The method of claim 7 , wherein R is selected from the group consisting of carbobenzyloxy; p-methoxybenzyl carbonyl; tert-butyloxycarbonyl; 9-fluorenylmethyloxycarbonyl; benzyl; p-methoxybenzyl; 3,4-dimethoxybenzyl; p-methoxyphenyl; tosyl; nosyl (4-nitrobenzenesulfonyl) and 2-nitrobenzenesulfonyl.
9. The method of claim 1 , wherein the diol comprises one or more ester groups, a pendant amino group or an amine.
10. The method of claim 9 , wherein the diol is a reaction product of a cyclic anhydride and a diol comprising one or more pendant active groups, blocked active groups or active agents.
11. The method of claim 10 , wherein the diol is the reaction product of succinic anhydride and the diol is an N-substituted serinol in which the N is substituted with one of a hydrogen, a protective group, or an active agent or
wherein the diol is a polymer or an oligomer with terminal primary alcohol functional group ends.
12. The method of claim 6 , wherein the diisocyanate is hexamethylene diisocyanate (1,6-diisocyanatohexane).
13. The method of claim 1 , wherein the copolymer comprises the structure:
in which R1 is H or a protective group, R2 is isocyanate or —NC(O)-polyethylene glycol (—NC(O)—PEG) and n is greater than 5, 8-30, 8-25 or 18-30.
14. The method of claim 1 , wherein the copolymer comprises the structure:
in which R1 is H or a protective group, R3 is PEG and n is greater than 5, 8-30, 8-25 or 18-30.
15. The method of claim 1 , wherein the copolymer comprises the structure:
in which R1 is H or a protective group or an active agent, R2 is isocyanate or —NC(O)—PEG and n is greater than 5, 8-30, 8-25 or 18-30.
16. The method of claim 1 , wherein the copolymer comprises the structure:
in which R1 is H or a protective group, R3 is PEG and n is greater than 5, 8-30, 8-25 or 18-30.
17. The method of claim 1 , wherein the triblock copolymer has an average molecular weight of between about 5,000 and 10,000 Da (Daltons), excluding, when present, the molecular weight of the active agent.
18. The method of claim 1 , wherein A is one of a polyurethane or poly(ester urethane) group that comprises one or more pendant charged or active groups.
19. The method of claim 18 , wherein the one or more pendant charged or active groups is —NH 2 .
20. The method of claim 1 , wherein an active agent is complexed to the triblock copolymer.
21. The method of claim 1 , wherein B is selected from the group consisting of polyethylene glycol (PEG), hyaluronan, poly(vinyl alcohol), oligo(vinyl alcohol), a poly(electrolyte), an oligo(electrolyte) and a polycarbohydrate.
22. The method of claim 1 , wherein the reverse thermal gel composition comprises poly(ethylene glycol)-poly(serinol hexamethylene urethane).
23. A method for increasing survival of a transplanted cell in a subject, comprising
transplanting into a subject a therapeutically effective amount of a cell; and
administering to the subject an effective amount of poly(ethylene glycol)-poly(serinol hexamethylene urethane),
thereby increasing the survival of the transplanted cell in the subject.
24. The method of claim 23 , wherein the cell is a mesenchymal stem cell, a bone marrow stem cell, stem cell, or a Schwann cell.
25. The method of claim 23 , wherein the subject has a neurodegenerative disorder, a stroke or a spinal cord injury.
26. The method of claim 23 , comprising administering the therapeutically effective amount of the mesenchymal cell and the effective amount of poly(ethylene glycol)-poly(serinol hexamethylene urethane) to the central nervous system or the peripheral nervous system.
27. The method of claim 23 , comprising administering the mesenchymal cell and the poly(ethylene glycol)-poly(serinol hexamethylene urethane) in an intraneural transplant.
28. The method of claim 23 , wherein increasing the survival of the cell comprises decreasing the production of reactive oxygen species.
29. A method of treating a subject with a spinal cord injury, stroke, or a neurodegenerative disorder, comprising administering to a subject a therapeutically effective amount of a cell; and administering to the subject a therapeutically effective amount of a reverse thermal gel composition comprising a triblock copolymer, or a pharmaceutically acceptable salt thereof, having the structure B-A-B in which A is one of a polyurethane or poly(ester urethane) group that comprises one or more pendant amine groups, blocked amine groups or active agents and B is a hydrophilic block, wherein the composition is a gel at 35° C. to 40° C. and a liquid solution at a lower temperature, and wherein A is a copolymer of a diol and a diisocyanate, thereby treating the spinal cord injury, stroke, or the neurodegenerative disorder.
30. The method of claim 29 , wherein the reverse thermal gel composition comprises an effective amount of poly(ethylene glycol)-poly(serinol hexamethylene urethane).
31. The method of claim 29 , further comprising administering the subject a therapeutically effective amount of a nerve growth factor.